Phaseline

Targets › CHRNA3

CHRNA3 (Neuronal acetylcholine receptor subunit alpha-3): drug programs, companies and trials

1 program from 1 company in 2 trials: 2 Phase 1; Cardiovascular; next expected readout Dec 2026.

Component of neuronal acetylcholine receptors (nAChRs) that function as pentameric, ligand-gated cation channels with high calcium permeability among other activities. nAChRs are excitatory neurotrasnmitter receptors formed by a collection of nAChR subunits known to mediate synaptic transmission in the nervous system and the neuromuscular junction. Each nAchR subunit confers differential attributes to channel…. (UniProt, P32297)

Open in Phaseline: the race on CHRNA3, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Vanderbilt UniversityTrimethaphan Camsylate
Neuronal acetylcholine receptor; alpha3/beta4 antagonist
CHRNB4, CHRNA3Phase 1Multiple System Atrophy; HypertensionDec 2026

Conditions

Multiple System Atrophy (1) Hypertension (1)

Modalities

small molecule (1)

Companies

Vanderbilt University (1)

Related targets

CHRNB4 (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.